Brian Pilecki, PhD - Portland Psychotherapy
Oregon Psilocybin Advisory Board (section of the Oregon Health Authority)
Oregon Psilocybin Advisory Board Rapid Evidence Review and Recommendations [PFD]
Scientific American. (2020, December). Psilocybin Treatment for Mental Health Gets Legal Framework
Multidisciplinary Association for Psychedelic Studies (MAPS) - Research
Michael Pollan. (2018). How to Change Your Mind: The New Science of Psychedelics.
References
Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020). A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. Journal of psychoactive drugs, 52(4), 289–299. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736164
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., ... & Griffiths, R. R. (2020). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry.
Carhart-Harris et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411.
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197.
Mitchell, J.M. et al. (2021). Phase 3 MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. https://doi.org/10.1038/s41591-021-01336-3
Watts, R., & Luoma, J.B.(2020). The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science, 15,92-102
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression.Journal of humanistic psychology,57(5), 520-564.
Cameron L.P., Nazarian A. & Olson, D.E. (2020) Psychedelic Microdosing: Prevalence and Subjective Effects, Journal of Psychoactive Drugs.
Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute andsustained subjective effects. Journal of Psychopharmacology, 29(1), 57–68.
Johnson, M.W., Garcia-Romeu, A., & Griffiths, R.R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 43(1), 55-60.
Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 9(JUN), 1–12.
Wilkinson, S.T., Ballard, E.D., Bloch, M.H. et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018; 175: 150–158